Acute Wound & Tissue Repair Protocol

Accelerate tissue healing, reduce inflammation, and restore functional integrity after acute injury, surgery, or chronic non-healing wounds

Patient profile: Adults with acute soft-tissue injuries, post-surgical wounds, chronic ulcers, or tendon/ligament tears requiring accelerated repair

Want a personalised protocol?

Our AI generator builds a protocol tailored to your profile and goals.

Generate protocol →

⚠️

This protocol is an educational example only. It does not apply to your specific health situation. Medical supervision is required. Peptide therapy is not approved by regulatory bodies for many of the described indications.

Protocol Stack

BPC-157

Primary

Dose

500 mcg

Frequency

1–2x/day SC

Timing

Morning (and optionally evening); near wound site if accessible

Duration

8 weeks

TB-500

Primary

Dose

5 mg

Frequency

2x/week SC (weeks 1–4), then 1x/week (weeks 5–8)

Timing

Any time, separate from BPC-157 by at least 2 hours

Duration

8 weeks

GHK-Cu

Supporting

Dose

Topical cream/serum (1–2% concentration)

Frequency

Apply 2x/day to wound surface or surrounding tissue

Timing

After wound cleaning, morning and evening

Duration

8 weeks (continue as needed)

Monitoring Parameters

✓Wound photography at baseline, week 2, week 4, week 8
✓Pain score (NRS 0–10) weekly
✓Signs of infection — temperature, erythema, exudate
✓Range of motion (for joint/tendon injuries) — biweekly
✓CBC and CRP if chronic wound or infection risk

Expected Outcomes

Weeks 1–2: Reduced local inflammation, pain scores decline 20–40%

Weeks 3–4: Visible wound closure acceleration, improved granulation tissue

Weeks 5–8: Full or near-full tissue repair; return to function

Contraindications

✗Active malignancy at or near wound site
✗Infected wound requiring antibiotic treatment first (peptides are adjunctive, not antimicrobial)
✗Known hypersensitivity to peptide components

Clinical Notes

BPC-157 and TB-500 have complementary mechanisms: BPC-157 primarily works via nitric-oxide pathway and growth-factor upregulation locally, while TB-500 (Thymosin Beta-4) acts systemically via actin sequestration and cell migration. Their combination is consistently reported as superior to either alone. GHK-Cu topically stimulates collagen synthesis and matrix metalloproteinase balance. For tendon/ligament injuries, BPC-157 injected proximal to the injury (not directly into the tendon) is standard practice.

Case Study

Clinical Practice Example

Male, 38, recreational runner. Achilles tendinopathy diagnosed by ultrasound (partial-thickness tear, 40% cross-section). Physiotherapy for 12 weeks produced only partial improvement. Added BPC-157 500 mcg/day SC + TB-500 5 mg 2x/week. Week 4: pain on palpation reduced from 7/10 to 3/10, ultrasound showed improved tendon structure. Week 8: full return to running, NRS 1/10 at peak load. Ultrasound at week 10: near-complete resolution of partial tear. No adverse events.

← Back to all protocols